TrialAlimentary pharmacology & therapeutics2019

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.

Mitchell Shiffman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.